HEADER SIGNALING PROTEIN/ANTAGONIST 16-NOV-11 3UON TITLE STRUCTURE OF THE HUMAN M2 MUSCARINIC ACETYLCHOLINE RECEPTOR BOUND TO TITLE 2 AN ANTAGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: HUMAN M2 MUSCARINIC ACETYLCHOLINE, RECEPTOR T4 LYSOZYME COMPND 3 FUSION PROTEIN; COMPND 4 CHAIN: A; COMPND 5 FRAGMENT: UNP RESIDUES 1-217, UNP RESIDUES 2-161, UNP RESIDUES 377- COMPND 6 466; COMPND 7 EC: 3.2.1.17; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS, ENTEROBACTERIA PHAGE T4; SOURCE 3 ORGANISM_TAXID: 9606, 10665; SOURCE 4 GENE: CHRM2, E; SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS G PROTEIN-COUPLED RECEPTOR, GPCR, ACETYLCHOLINE RECEPTOR, SIGNALING KEYWDS 2 PROTEIN-ANTAGONIST COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR K.HAGA,A.C.KRUSE,H.ASADA,T.YURUGI-KOBAYASHI,M.SHIROISHI,C.ZHANG, AUTHOR 2 W.I.WEIS,T.OKADA,B.K.KOBILKA,T.HAGA,T.KOBAYASHI REVDAT 6 06-NOV-24 3UON 1 REMARK REVDAT 5 13-SEP-23 3UON 1 HETSYN REVDAT 4 29-JUL-20 3UON 1 COMPND REMARK SEQADV HETNAM REVDAT 4 2 1 SITE REVDAT 3 09-AUG-17 3UON 1 SOURCE REMARK REVDAT 2 28-MAR-12 3UON 1 JRNL REVDAT 1 01-FEB-12 3UON 0 JRNL AUTH K.HAGA,A.C.KRUSE,H.ASADA,T.YURUGI-KOBAYASHI,M.SHIROISHI, JRNL AUTH 2 C.ZHANG,W.I.WEIS,T.OKADA,B.K.KOBILKA,T.HAGA,T.KOBAYASHI JRNL TITL STRUCTURE OF THE HUMAN M2 MUSCARINIC ACETYLCHOLINE RECEPTOR JRNL TITL 2 BOUND TO AN ANTAGONIST. JRNL REF NATURE V. 482 547 2012 JRNL REFN ISSN 0028-0836 JRNL PMID 22278061 JRNL DOI 10.1038/NATURE10753 REMARK 2 REMARK 2 RESOLUTION. 3.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (PHENIX.REFINE: 1.7.1_743) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 27.47 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 94.2 REMARK 3 NUMBER OF REFLECTIONS : 11702 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.227 REMARK 3 R VALUE (WORKING SET) : 0.225 REMARK 3 FREE R VALUE : 0.276 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.070 REMARK 3 FREE R VALUE TEST SET COUNT : 593 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 0.50 REMARK 3 SHRINKAGE RADIUS : 0.16 REMARK 3 K_SOL : 0.36 REMARK 3 B_SOL : 52.88 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.700 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 30.110 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 18.22780 REMARK 3 B22 (A**2) : 2.57710 REMARK 3 B33 (A**2) : -20.80490 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 9.84640 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.002 3577 REMARK 3 ANGLE : 0.573 4880 REMARK 3 CHIRALITY : 0.041 582 REMARK 3 PLANARITY : 0.002 592 REMARK 3 DIHEDRAL : 12.894 1261 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3UON COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 17-NOV-11. REMARK 100 THE DEPOSITION ID IS D_1000069016. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-FEB-11; 05-MAR-11 REMARK 200 TEMPERATURE (KELVIN) : 78; 78 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 23 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y; Y REMARK 200 RADIATION SOURCE : APS; APS REMARK 200 BEAMLINE : 23-ID-D; 23-ID-B REMARK 200 X-RAY GENERATOR MODEL : NULL; NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M; M REMARK 200 WAVELENGTH OR RANGE (A) : 1.033; 1.033 REMARK 200 MONOCHROMATOR : SI(111) DOUBLE CRYSTAL; SI(111) REMARK 200 DOUBLE CRYSTAL REMARK 200 OPTICS : MIRRORS; MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD; CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD; MARMOSAIC REMARK 200 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11726 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.000 REMARK 200 RESOLUTION RANGE LOW (A) : 27.500 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.1 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.18500 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 6.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.05 REMARK 200 COMPLETENESS FOR SHELL (%) : 79.2 REMARK 200 DATA REDUNDANCY IN SHELL : 2.40 REMARK 200 R MERGE FOR SHELL (I) : 0.45400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH; SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: BETA2 ADRENERGIC RECEPTOR, T4 LYSOZYME (PDB ENTRY REMARK 200 2RH1) REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.70 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.91 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25 TO 35% PEG 300, 100 MM AMMONIUM REMARK 280 PHOSPHATE, 2% 2-METHYL-2,4-PENTANEDIOL, 100 MM HEPES, 10:1 REMARK 280 MONOOLEIN:CHOLESTEROL LIPID MIX DILUTED 1.5:1 WITH PROTEIN IN REMARK 280 DETERGENT BUFFER, LIPIDIC CUBIC PHASE, TEMPERATURE 293K, PH 7.5 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 23.63000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE BIOLOGICAL MOLECULE IS EQUIVALENT TO THE CONTENTS OF REMARK 300 THE ASYMMETRIC UNIT EXCLUDING THE T4 LYSOZYME, WHICH IS A NON- REMARK 300 PHYSIOLOGICAL CRYSTALLIZATION AID. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 ASP A 2 REMARK 465 ASP A 3 REMARK 465 SER A 4 REMARK 465 THR A 5 REMARK 465 ASP A 6 REMARK 465 SER A 7 REMARK 465 SER A 8 REMARK 465 ASP A 9 REMARK 465 ASN A 10 REMARK 465 SER A 11 REMARK 465 LEU A 12 REMARK 465 ALA A 13 REMARK 465 LEU A 14 REMARK 465 THR A 15 REMARK 465 SER A 16 REMARK 465 PRO A 17 REMARK 465 TYR A 18 REMARK 465 LYS A 19 REMARK 465 CYS A 457 REMARK 465 HIS A 458 REMARK 465 TYR A 459 REMARK 465 LYS A 460 REMARK 465 ASN A 461 REMARK 465 ILE A 462 REMARK 465 GLY A 463 REMARK 465 ALA A 464 REMARK 465 THR A 465 REMARK 465 ARG A 466 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 216 CG CD NE CZ NH1 NH2 REMARK 470 LYS A1016 CG CD CE NZ REMARK 470 LYS A1019 CG CD CE NZ REMARK 470 GLU A1022 CG CD OE1 OE2 REMARK 470 TYR A1024 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 TYR A1025 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 MET A 456 CG SD CE REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 75 -67.42 -102.90 REMARK 500 LEU A1033 -67.90 -108.18 REMARK 500 ASN A1055 -1.55 69.92 REMARK 500 SER A 380 -19.28 71.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE STRUCTURE IS AN INTERNAL FUSION PROTEIN WITH LYSOZYME. AN REMARK 999 OFFSET 1000 HAS BEEN ADDED TO ORIGINAL SEQUENCE DATABASE RESIDUE REMARK 999 NUMBERS (2-161) OF THE LYSOZYME PART IN COORDINATES TO DISTINGUISH REMARK 999 THE LYSOZYME PART IN THE CHAIN. THEREFORE LYSOZYME PART HAVE REMARK 999 NUMBERS A1002-A1161. DBREF 3UON A 1 217 UNP P08172 ACM2_HUMAN 1 217 DBREF 3UON A 1002 1161 UNP P00720 LYS_BPT4 2 161 DBREF 3UON A 377 466 UNP P08172 ACM2_HUMAN 377 466 SEQADV 3UON ASP A 2 UNP P08172 ASN 2 ENGINEERED MUTATION SEQADV 3UON ASP A 3 UNP P08172 ASN 3 ENGINEERED MUTATION SEQADV 3UON ASP A 6 UNP P08172 ASN 6 ENGINEERED MUTATION SEQADV 3UON ASP A 9 UNP P08172 ASN 9 ENGINEERED MUTATION SEQADV 3UON THR A 1054 UNP P00720 CYS 54 ENGINEERED MUTATION SEQADV 3UON ALA A 1097 UNP P00720 CYS 97 ENGINEERED MUTATION SEQRES 1 A 467 MET ASP ASP SER THR ASP SER SER ASP ASN SER LEU ALA SEQRES 2 A 467 LEU THR SER PRO TYR LYS THR PHE GLU VAL VAL PHE ILE SEQRES 3 A 467 VAL LEU VAL ALA GLY SER LEU SER LEU VAL THR ILE ILE SEQRES 4 A 467 GLY ASN ILE LEU VAL MET VAL SER ILE LYS VAL ASN ARG SEQRES 5 A 467 HIS LEU GLN THR VAL ASN ASN TYR PHE LEU PHE SER LEU SEQRES 6 A 467 ALA CYS ALA ASP LEU ILE ILE GLY VAL PHE SER MET ASN SEQRES 7 A 467 LEU TYR THR LEU TYR THR VAL ILE GLY TYR TRP PRO LEU SEQRES 8 A 467 GLY PRO VAL VAL CYS ASP LEU TRP LEU ALA LEU ASP TYR SEQRES 9 A 467 VAL VAL SER ASN ALA SER VAL MET ASN LEU LEU ILE ILE SEQRES 10 A 467 SER PHE ASP ARG TYR PHE CYS VAL THR LYS PRO LEU THR SEQRES 11 A 467 TYR PRO VAL LYS ARG THR THR LYS MET ALA GLY MET MET SEQRES 12 A 467 ILE ALA ALA ALA TRP VAL LEU SER PHE ILE LEU TRP ALA SEQRES 13 A 467 PRO ALA ILE LEU PHE TRP GLN PHE ILE VAL GLY VAL ARG SEQRES 14 A 467 THR VAL GLU ASP GLY GLU CYS TYR ILE GLN PHE PHE SER SEQRES 15 A 467 ASN ALA ALA VAL THR PHE GLY THR ALA ILE ALA ALA PHE SEQRES 16 A 467 TYR LEU PRO VAL ILE ILE MET THR VAL LEU TYR TRP HIS SEQRES 17 A 467 ILE SER ARG ALA SER LYS SER ARG ILE ASN ILE PHE GLU SEQRES 18 A 467 MET LEU ARG ILE ASP GLU GLY LEU ARG LEU LYS ILE TYR SEQRES 19 A 467 LYS ASP THR GLU GLY TYR TYR THR ILE GLY ILE GLY HIS SEQRES 20 A 467 LEU LEU THR LYS SER PRO SER LEU ASN ALA ALA LYS SER SEQRES 21 A 467 GLU LEU ASP LYS ALA ILE GLY ARG ASN THR ASN GLY VAL SEQRES 22 A 467 ILE THR LYS ASP GLU ALA GLU LYS LEU PHE ASN GLN ASP SEQRES 23 A 467 VAL ASP ALA ALA VAL ARG GLY ILE LEU ARG ASN ALA LYS SEQRES 24 A 467 LEU LYS PRO VAL TYR ASP SER LEU ASP ALA VAL ARG ARG SEQRES 25 A 467 ALA ALA LEU ILE ASN MET VAL PHE GLN MET GLY GLU THR SEQRES 26 A 467 GLY VAL ALA GLY PHE THR ASN SER LEU ARG MET LEU GLN SEQRES 27 A 467 GLN LYS ARG TRP ASP GLU ALA ALA VAL ASN LEU ALA LYS SEQRES 28 A 467 SER ARG TRP TYR ASN GLN THR PRO ASN ARG ALA LYS ARG SEQRES 29 A 467 VAL ILE THR THR PHE ARG THR GLY THR TRP ASP ALA TYR SEQRES 30 A 467 PRO PRO PRO SER ARG GLU LYS LYS VAL THR ARG THR ILE SEQRES 31 A 467 LEU ALA ILE LEU LEU ALA PHE ILE ILE THR TRP ALA PRO SEQRES 32 A 467 TYR ASN VAL MET VAL LEU ILE ASN THR PHE CYS ALA PRO SEQRES 33 A 467 CYS ILE PRO ASN THR VAL TRP THR ILE GLY TYR TRP LEU SEQRES 34 A 467 CYS TYR ILE ASN SER THR ILE ASN PRO ALA CYS TYR ALA SEQRES 35 A 467 LEU CYS ASN ALA THR PHE LYS LYS THR PHE LYS HIS LEU SEQRES 36 A 467 LEU MET CYS HIS TYR LYS ASN ILE GLY ALA THR ARG HET QNB A1162 25 HET BGC A1163 12 HET CL A1164 1 HET CL A1165 1 HETNAM QNB (3R)-1-AZABICYCLO[2.2.2]OCT-3-YL HYDROXY(DIPHENYL) HETNAM 2 QNB ACETATE HETNAM BGC BETA-D-GLUCOPYRANOSE HETNAM CL CHLORIDE ION HETSYN BGC BETA-D-GLUCOSE; D-GLUCOSE; GLUCOSE FORMUL 2 QNB C21 H23 N O3 FORMUL 3 BGC C6 H12 O6 FORMUL 4 CL 2(CL 1-) FORMUL 6 HOH *57(H2 O) HELIX 1 1 GLU A 22 ASN A 51 1 30 HELIX 2 2 ARG A 52 GLN A 55 5 4 HELIX 3 3 THR A 56 PHE A 75 1 20 HELIX 4 4 PHE A 75 ILE A 86 1 12 HELIX 5 5 GLY A 92 LYS A 127 1 36 HELIX 6 6 TYR A 131 ARG A 135 5 5 HELIX 7 7 THR A 136 GLY A 167 1 32 HELIX 8 8 ILE A 178 SER A 182 5 5 HELIX 9 9 ASN A 183 PHE A 195 1 13 HELIX 10 10 PHE A 195 LYS A 214 1 20 HELIX 11 11 ASN A 1002 GLU A 1011 1 10 HELIX 12 12 SER A 1038 GLY A 1051 1 14 HELIX 13 13 THR A 1059 ARG A 1080 1 22 HELIX 14 14 LEU A 1084 LEU A 1091 1 8 HELIX 15 15 ASP A 1092 ALA A 1112 1 21 HELIX 16 16 PHE A 1114 GLN A 1123 1 10 HELIX 17 17 ARG A 1125 ALA A 1134 1 10 HELIX 18 18 SER A 1136 THR A 1142 1 7 HELIX 19 19 THR A 1142 GLY A 1156 1 15 HELIX 20 20 LYS A 383 CYS A 413 1 31 HELIX 21 21 PRO A 418 ASN A 432 1 15 HELIX 22 22 THR A 434 ASN A 444 1 11 HELIX 23 23 ASN A 444 LEU A 455 1 12 SHEET 1 A 3 ARG A1014 LYS A1019 0 SHEET 2 A 3 TYR A1025 GLY A1028 -1 O GLY A1028 N ARG A1014 SHEET 3 A 3 HIS A1031 LEU A1032 -1 O HIS A1031 N ILE A1027 SSBOND 1 CYS A 96 CYS A 176 1555 1555 2.03 SSBOND 2 CYS A 413 CYS A 416 1555 1555 2.03 CRYST1 78.170 47.260 88.120 90.00 109.70 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012793 0.000000 0.004585 0.00000 SCALE2 0.000000 0.021159 0.000000 0.00000 SCALE3 0.000000 0.000000 0.012056 0.00000